INM vs NMTC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
INM Captures Institutional Edge (2โ1 Pillars ยท 3โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to InMed Pharmaceuticals Inc. Common Shares (INM) driven by superior Growth & Margin, Momentum & Technical while NMTC counters with relative strength in Options & Structure. Fundamentally, INM trades at N/M Forward P/E with 0.0% operating margin (-26.2% YoY revenue) versus NMTC at N/M Forward P/E and -63.4% operating margin (+16.3% YoY). In options structure, INM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against NMTC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | INM Revenue | NMTC Revenue | INM Op. Margin | NMTC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2012 | N/A | $0M | N/A | -1491.1% | NMTC |
| FY2013 | N/A | $0M | N/A | -2009.0% | NMTC |
| FY2014 | N/A | $0M | N/A | -4646.1% | NMTC |
| FY2021 | $0M | $0M | -535.9% | -5735.9% | INM |
| FY2022 | $0M | $0M | -1361.9% | -5860.2% | INM |
| FY2023 | $0M | $0M | -192.2% | -612.3% | INM |
| FY2024 | $0M | $0M | -166.9% | -344.3% | INM |
| FY2025 | $0M | $10M | -165.1% | -46.5% | NMTC |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | INM | NMTC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.3M | $6.1M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -26.2% | +16.3% | Higher Growth | NMTC |
| Operating Margin (TTM) Profitability | 0.0% | -63.4% | Higher Margin | INM |
| Net Profit Margin Profitability | 0.0% | -59.7% | Higher Margin | INM |
| Return on Equity (ROE) Capital Efficiency | -222.1% | -124.7% | Higher ROE | NMTC |
| 52-Week Range Position Momentum | 94% ($1โ$16) | 2% ($1โ$5) | Stronger Trend | INM |
| Beta / 30D Volatility Risk Regime | -20.85ฮฒ ยท 2208% Vol | 1.55ฮฒ ยท 105% Vol | Lower Realized Risk | NMTC |
| Unified Institutional Score Composite Signal | 35.6 / 100 (SELL) | 45.5 / 100 (HOLD) | Higher Composite | NMTC |